Background: Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties,but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is stillunknown.Methods: A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history ofcoronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by colordoppler ultrasound.Results: After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p<0.01 for all). Liraglutidereduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by18% (p < 0.01 for all lipid changes). Carotid IMT decreased from 1.19 ± 0.47 to 0.94 ± 0.21 mm (p < 0.01). Yet, changes incarotid IMT did not correlate with changes in any other variable studied.Conclusions: Liraglutide decreases carotid IMT after 8 months treatment independently of its effect on plasma glucoseand lipids concentrations.
|Numero di pagine||5|
|Stato di pubblicazione||Published - 2014|
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Cardiology and Cardiovascular Medicine